Subscribe
Healthcare

Senate approval for drug pricing reforms will be uphill battle, advocates warn

By Cassidy Morrison
Published
Add Washington Examiner on Google
Senate approval for drug pricing reforms will be uphill battle, advocates warn

Efforts to push a proposal for direct drug pricing negotiations between the government and pharmaceutical companies over the finish line will face a steep uphill battle, liberal health reform groups warn.

Big Pharma is a monopoly industry, according to David Mitchell, founder of Patients For Affordable Drugs NOW.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

Biden Administration Democrats Drug Policy House Energy and Commerce Committee Medicare and Medicaid Nancy Pelosi Ron Wyden Tom Carper